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Clinical courseTaxane and platinum-based chemotherapy regimens are standard treatment for advanced ovarian carcinoma.
Expression levels of putative markers of taxane resistance in carcinoma tissues and paired peritoneal samples
(n = 55) and in 16 samples of ovaries without signs of carcinomawere comparedwith clinical data and the pa-
tients' time to progression. KIF14, PRC1, CIT and ABCC1 genes were signiﬁcantly overexpressed in carcinomas
when compared with normal ovarian tissues, while ABCB1 and CASP9 expression was decreased. Associations
of protein expression of the proliferation marker Ki-67 with KIF14, PRC1, ABCB1 and CASP2 were found. Lastly,
it was discovered that ABCB1 and CASP2 levels associated with FIGO stage and that the CIT level associated
with the time to progression of ovarian carcinoma patients (P b 0.0001).
In conclusion, ABCB1, CASP2, KIF14, PRC1 and CIT genes seem to associate with surrogate markers of ovarian
carcinoma progression and CIT gene associates with therapy outcome.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Surgical tumor debulking followed by platinum-based and pacli-
taxel chemotherapy is the standard treatment for advanced ovarian
carcinoma. Objective responses to it are observed in approximately
60–80% of patients treated in the front-line setting. However, despite
the high response rate to the initial chemotherapy, the majority of pa-
tients will experience recurrence [1], with only about 44% surviving 5
years after the diagnosis [2]. The chemoresistance of ovarian carcino-
ma caused by multiple factors [3] contributes to this fact. Molecular
markers of the efﬁcacy and resistance of taxane-based therapies in
ovarian carcinoma need to be identiﬁed and subsequently validated.
Classical taxanes paclitaxel (Taxol) and docetaxel (Taxotere) are
mitotic poisons that stimulate polymerization of microtubules and in-
hibit their depolymerization (Spencer and Faulds 1994). Mirotubules
play an important role in the correct function of mitotic spindle dur-
ing cytokinesis and cooperate with a number of proteins involved in
this process. Mitotic kinesins and microtubule-associated proteins
(MAPs) act in concert to direct cytokinesis [4]. Molecular motorsonal Institute of Public Health,
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[5] and may be considered as putative markers of taxane resistance. A
mitotic kinesin KIF14 (OMIM: 611279) targets the central spindle via
its interaction with protein-regulating cytokinesis 1 (PRC1, OMIM:
603484) and has an essential function in cytokinesis [6]. Very recent-
ly, the expression of KIF14was found to be an independent prognostic
marker in serous ovarian carcinoma [7]. Citron kinase (CIT, OMIM:
605629), a protein required for cytokinesis and conserved from in-
sects to mammals, is currently considered a cytokinesis-speciﬁc regu-
lator of active RhoA [8]. Nevertheless, the role of KIF14-related genes
in the prognosis and chemotherapy outcome of cancer patients is not
well understood.
In previous studies we have also documented the involvement of
paclitaxel, docetaxel and experimental taxanes in the induction of
apoptosis in vitro [9,10], which is mediated by the caspase family of
proteases that act as effectors of cell death by cleaving various cellular
substrates. The effector caspase-3 (OMIM: 600636, encoded by CASP3)
has been identiﬁed as principal enzyme in the apoptotic cascade and is
often used to detect apoptotic activity [11]. Moreover, caspases-2, -8
and -9 (OMIM: 600639, 601763 and 602234) are important initiator
caspases involved in apoptosis [summarized in 11,12]. It was discovered
that caspase-3 activates procaspase-2 and caspase-2-mediated apopto-
sis requires caspase-9 [13]. Lower expression of caspase-3 is typical
for chemotherapy-resistant ovarian carcinomas [14] and may thus
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the gene expression patterns of CASP2, 8 and 9 and their roles in ovarian
carcinoma clinical course have not been reported so far.
Finally, efﬂux of taxanes from tumor cells has been reported to be
associatedwith function ofmainly twomembers of the ATP binding cas-
sette (ABC) membrane transporter family; ABCB1 and ABCC1 (OMIM:
171050 and 158343) [summarized in 15,16]. Studies have shown that
in ovarian carcinoma, ABCB1 gene/protein expression is associated
with multidrug resistance [17,18]. ABCC1 transcript level has also been
found to be signiﬁcantly higher in ovarian carcinoma lesions compared
with cystadenomas and normal ovarian tissues [19] and seems to be
another putative taxane resistance gene.
With regard to the above-mentioned factors, the aimof this studywas
to explore the role of incompletely characterized putative markers of re-
sistance to taxanes in the clinical course of ovarian carcinoma. Particular
attention was paid to the effects of KIF14 and related genes (PRC1 and
CIT), apoptotic pathway effectors/initiators (CASP2, 3, 8 and 9) and
major drug transporters (ABCB1 and ABCC1) on the clinical characteristics
and therapy outcome of patients.
2. Results
2.1. Characteristics of patients
The study population consisted of 55 patients with ovarian carcino-
mas and 16 patients withoutmorphological/macroscopic signs of carci-
noma in their ovaries (uterine leiomyoma, n = 9; benign ovarian cyst,
n = 2; cervical carcinoma, n = 4; sarcoma, n = 1). Paired samples
from peritoneal epithelium without morphological/macroscopic signs
of carcinoma were available for 51 ovarian carcinoma patients. The
clinical characteristics of patients involved in the study are described
in Table 1. The median age of ovarian carcinoma patients at diagnosis
(59.7 ± 12.0 years) did not signiﬁcantly differ from the age of pa-
tients whose normal ovarian tissues were used for comparison
(57.6 ± 12.7 years). The average Ki-67 (MKI67) expression in carci-
nomas was 38.7 ± 24.4 while in the non-neoplastic ovarian tissues it
was ≤1%. The majority of patients (93%) received adjuvant chemothe-
rapy with a combination of taxane (paclitaxel) and platinum derivative
(carbo-platinum or cis-platinum). Four patients (7%) received onlyTable 1
Clinical characteristics of ovarian carcinoma patients.
Characteristics N (%)a
Median age at diagnosis, years 59.7 ± 12.0
FIGO stage
I 3 (5.5)
II 6 (11.0)
III 40 (72.6)
IV 5 (9.1)
Not available 1 (1.8)
Histological type
Serous adenocarcinoma 38 (69.1)
Mucinous adenocarcinoma 4 (7.3)
Clear cell adenocarcinoma 3 (5.5)
Unspeciﬁed adenocarcinoma or other 10 (18.1)
Histological grade
1 5 (9.1)
2 11 (20.0)
3 31 (56.4)
4 7 (12.7)
Not available 1 (1.8)
Residual tumor after surgery
Present 34 (61.8)
Absent 20 (36.4)
Not available 1 (1.8)
Ki-67 protein expression
mean ± S.D., % 38.7 ± 24.4
Not available 2 (3.6)
a Number of patients with percentage in parentheses is shown.carbo-platinum during adjuvant chemotherapy. Eight (14.5%) patients
received neoadjuvant chemotherapywith no effect on the evaluated as-
sociations (analyses with vs. without patients treated by neoadjuvant
therapy) in this study.
The median follow up was 32 ± 2 months. Altogether there were
20 (41%) progressions or carcinoma-related deaths (events) among
the 49 patients who were evaluated. Five patients were excluded
from time to progression (TTP analyses as lost to follow up (n = 4)
or due to postoperative mortality (n = 1).
2.2. Transcript levels of target genes
Transcripts of the analyzed genes (Table 2) were detected by quanti-
tative real-time PCR (qPCR) in all available tissue samples included in
the study. Signiﬁcantly higher transcript levels of KIF14, CIT, PRC1 and
ABCC1 in carcinoma tissues were found, when compared with either
the independent set of normal ovarian tissues (Table 3A) or the paired
peritoneal tissues (Table 3B). In contrast, ABCB1 and CASP9 levels were
signiﬁcantly decreased in carcinoma tissues, when compared with
either normal ovarian tissues (Table 3A) or paired peritoneal tissues
(Table 3B). CASP2, CASP3 and CASP8 levels were not signiﬁcantly differ-
ent between carcinoma and normal ovarian tissues (Table 3A). Similarly
the CASP8 transcript levels did not differ between carcinoma and paired
peritoneal tissues either (Table 3B). However, overexpression of CASP2
and decreased expression of CASP3were found in carcinoma compared
with paired peritoneal tissues (Table 3B). The observed differences in
transcript levels of all genes between ovarian carcinoma tissues and
normal ovarian tissues were not inﬂuenced by exclusion of two benign
ovarian cysts from analyses.
2.3. Associations between transcript levels and clinical characteristics
Transcript levels of target genes in ovarian carcinoma tissues were
evaluated for their associations with clinical characteristics and the
TTP of patients. The results of this evaluation are as follows: A negative
correlation was found between the PRC1 level in ovarian carcinoma tis-
sues and the age of patients at the time of diagnosis (P = 0.046, data not
shown). CASP2 levels were signiﬁcantly higher in carcinoma tissues of
patients with the more advanced FIGO stages III or IV when compared
with stages I or II (Table 4). Conversely, theABCB1 level was signiﬁcantly
higher in patients with the less advanced FIGO stages I or II compared
with patients in stages III or IV (Table 4).KIF14 and PRC1 levels positively
correlatedwith the expression of Ki-67 (P b 0.0001 both, Table 4). There
was a negative correlation between the ABCB1 level and the Ki-67 level,
whereas CASP2 correlated positively (P = 0.003 and P = 0.016, respec-
tively, Table 4). Transcript levels of CIT, ABCC1, CASP3, 8 and 9 did not
associate with any of the analyzed clinical characteristics. Similarly, the
histological type and grade of the ovarian carcinomas did not associate
with any of the studied genes. However, a strong association was
observed between CIT level and TTP (Fig. 1). In particular, patients with
the highest intratumoral CIT level (cut off 75th quartile) had signiﬁcantly
better TTP than patients with low expression levels (P = b0.0001).
Neoadjuvant chemotherapy did not signiﬁcantly affect any of the
evaluated associations (analyses with vs. without patients treated by
neoadjuvant therapy).
3. Discussion
Ovarian carcinoma patients are often diagnosed at the advanced
FIGO stages III and IV, and thus have very poor prognosis [2,20].
Currently, there are no recognized molecular markers of ovarian car-
cinoma prognosis. FIGO stage, grade and type of the tumor, residual
tumor volume after surgery, age and performance status of patients
are used clinically as prognostic markers. From experience with
other epithelial carcinomas, e.g. breast carcinoma (MammaPrint or
Oncotype DX), it is clear that genetic markers that could enable a
Table 2
Gene expression assays used in the study.
Gene symbol Assay ID GenBank accession no. Gene name Amplicon
length (bp)
Molecular function
Reference genes
PPIA 4333763F NM_021130.3 Peptidylprolyl isomerase A 98 Cyclosporin binding protein
TBP Hs00920495m1 NM_003194.4 TATA box binding protein 112 General transcription factor
GUSB Hs99999908m1 NM_000181.3 Beta-glucuronidase 81 Degradation of glucuronic acid-containing
glycosaminoglycans
Target genes
KIF14 Hs00978216m1 NM_014875.2 Kinesin family member 14 119 Intracellular transport and cell division
CIT Hs00392339m1 NM_001206999.1 Citron (rho-interacting, serin/threonine kinase 21) 68 Cytokinesis
PRC1 Hs00187740m1 NM_003981.2 Protein regulator of cytokinesis 1 66 Cytokinesis
ABCB1 Hs00184491m1 NM_000927.4 ATP-binding cassette transporter (subfamily B) 110 Transport of drugs across cellular membranes
ABCC1 Hs00219905m1 NM_004996.3 ATP-binding cassette (subfamily C) 74 Transport of drugs across cellular membranes
CASP2 Hs00234982m1 NM_032982.3 Caspase-2, apoptosis-related cysteine peptidase 56 Apoptosis-related factor
CASP3 Hs00234387m1 NM_004346.3 Caspase-3, apoptosis-related cysteine peptidase 100 Apoptosis-related factor
CASP8 Hs01018151m1 NM_001080124.1 Caspase-3, apoptosis-related cysteine peptidase 124 Apoptosis-related factor
CASP9 Hs00154260m1 NM_001229.3 Caspase-9, apoptosis-related cysteine peptidase 71 Apoptosis-related factor
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noses may also exist for ovarian carcinoma patients. If such markers
were to be discovered, it would enable the chemotherapy regimens
for treating patients with ovarian carcinoma to be tailored to the indi-
vidual. It is mostly taxane- and platinum-based regimens that are
used for chemotherapy in patients with ovarian carcinoma. Therefore,
it is possible to study a fairly homogeneous patient group in terms
of chemotherapy. It was our aim to explore the in vivo importance
for ovarian carcinoma clinical course of in vitrowell established puta-
tive molecular markers that are associated with resistance toward
taxanes.Table 3
Differences in the relative transcript levels of target genes between ovarian carcinomas
and (A) normal ovarian tissue samples or (B) adjacent peritoneal tissue samples from
the same patients.
A)
Gene Typea Reaction
efﬁciency
Expression
difference
Pb Carcinoma vs.
normal ovary
PPIA REF 93% 1.53
TBP REF 92% 0.80
GUSB REF 96% 0.83
KIF14 TRG 96% 19.75 b0.001 Overexpression
CIT TRG 100% 8.12 b0.001 Overexpression
PRC1 TRG 94% 6.44 b0.001 Overexpression
ABCB1 TRG 89% 0.37 b0.001 Decreased expression
ABCC1 TRG 89% 1.47 0.002 Overexpression
CASP2 TRG 90% 1.07 0.567
CASP3 TRG 91% 1.14 0.217
CASP8 TRG 98% 1.19 0.183
CASP9 TRG 100% 0.31 b0.001 Decreased expression
B)
Gene Typea Reaction
efﬁciency
Expression
difference
Pb Carcinoma vs.
peritoneum
PPIA REF 93% 1.05
TBP REF 92% 0.95
GUSB REF 96% 1.00
KIF14 TRG 96% 7.06 b0.001 Overexpression
CIT TRG 100% 2.21 b0.001 Overexpression
PRC1 TRG 94% 3.69 b0.001 Overexpression
ABCB1 TRG 92% 0.18 b0.001 Decreased expression
ABCC1 TRG 89% 1.38 b0.001 Overexpression
CASP2 TRG 90% 1.32 0.001 Overexpression
CASP3 TRG 98% 0.72 b0.001 Decreased expression
CASP8 TRG 98% 0.85 0.079
CASP9 TRG 100% 0.80 0.011 Decreased expression
a REF = reference gene, TRG = target gene.
b P-value by REST2009 software program.Taxanes bind to tubulin and inhibit microtubule disassembly, subse-
quently resulting in cell cycle arrest in theG2/Mphase and impairing the
mitotic activity of malignant cells. Members of the kinesin superfamily
appear to be important regulatory proteins in these processes [5].
Thériault et al. [7] found a genomic gain ofKIF14 in 30% of serous ovarian
carcinomas and an elevation of KIF14 mRNA in 91% of carcinomas vs.
normal epithelium (deﬁned as four normal tubal epithelium tissues
and twelve short-term cultures of primary ovarian surface epithelium
samples). It indicated that a high KIF14 transcript level in carcinomas in-
dependently predicted worse progression-free survival in patients with
serous ovarian carcinomas (P = 0.03) [7]. In agreementwith these con-
clusions, our study found an almost 20-fold overexpression of KIF14
transcript in ovarian carcinoma in comparison with normal ovarian
tissues (P b 0.001). Moreover, the 7-fold overexpression in carcinoma
compared with paired peritoneal tissue from the same patients
that we observed in our study further underlined the importance
of KIF14 overexpression in ovarian carcinogenesis. The suggested prog-
nostic value of KIF14 [7] was underlined in our study by its strong asso-
ciation with the proliferation marker Ki-67 (P b 0.0001). PRC1 is a
microtubule-associated protein with an essential function for spindle
integrity during late mitosis in mammalian cells and similarly as CIT in-
teracts with KIF14 [6]. The expression of PRC1 and CIT was strongly
overexpressed in ovarian carcinoma tissues in our study and PRC1 was
signiﬁcantly associated with Ki-67 expression (P b 0.0001). The expres-
sion of CIT was signiﬁcantly elevated in our ovarian carcinoma patients
with better TTP (P b 0.0001). Given the previously reported lack of asso-
ciation of expression levels of CITwith the survival times of ovarian car-
cinoma patients [7] the role of CIT observed by us seems contradictory.
However, a recent study demonstrated that low-grade serous carcinoma
is less chemosensitive than its high-grade counterpart [21]. Therefore, itTable 4
Associations between transcript levels of the investigated genes in ovarian carcinomas
and clinical-pathologic data of ovarian carcinoma patients.
Gene FIGO stage Ki-67 protein expression
I or II III or IV Signiﬁcance
ABCB1 1.31 ± 0.03a 1.35 ± 0.06 ρ = −0.407
P = 0.021b P = 0.003c
PRC1 ρ = 0.485
NS P b 0.0001c
KIF14 ρ = 0.467
NS P b 0.0001c
CASP2 1.10 ± 0.03 1.06 ± 0.03 ρ = 0.331
P = 0.020b P = 0.016c
a Target gene/REF values ± SD.
b P-values by Kruskal–Wallis test.
c P-values by Spearman correlation; ρ = Spearman's correlation coefﬁcient.
Fig. 1. Association of transcript level of CIT with time-to-progression of ovarian carcinoma patients. Kaplan–Meier survival curves are shown for two groups of patients divided by
cut-off (75th quartile) with respect to the normalized transcript levels of CIT in their carcinoma tissue. Dotted line represents the group of patients with low CIT expression level
(mean survival 16.9 ± 3.5 months, n = 12) and solid line represents the group with high CIT expression level (mean survival 33.3 ± 2.5 months, n = 37). The difference between
the mean TTP of patients divided by the CIT transcript level was signiﬁcant (P = b0.0001, Log Rank test).
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with TTP may have reﬂected the higher chemosensitivity of high-grade
ovarian carcinomas (almost 70% grade 3 or 4 in our patients). Based on
our observations, KIF14, PRC1 and CIT seem to constitute a part of a path-
way signiﬁcantly associated with surrogate markers of progression
of ovarian carcinoma. Short period of the follow up of patients may be
seen as limitation of the present study. Thus, the association of CIT
with TTP of ovarian carcinoma patients should be considered as prelim-
inary and needs further evaluation.
ABC transporters are responsible for the efﬂux of anticancer drugs
through the cell membrane that reduces the intracellular levels of
drugs in carcinoma cells. A signiﬁcant elevation of four ABC transporter
genes (ABCC1, ABCC2, ABCC3 and ABCB3) in recurrent (post-treatment,
n = 50) ovarian carcinoma lesionswhen comparedwith cystadenomas
andnormal ovarian tissues (n = 50) and primary pre-treatment lesions
(n = 50) was recently reported [19]. Authors concluded that this
ﬁnding supports the concept that chemotherapy resistance in ovarian
carcinoma develops during the course of chemotherapy itself [19]. We
have observed a signiﬁcant overexpression of the ABCC1 transcript
level in ovarian carcinoma tissues before chemotherapy when com-
pared with paired peritoneal or independent normal ovarian tissues.
Our results are in line with the ABCC1 overexpression in primary
untreated ovarian carcinomas reported by Ohishi et al. [22]. In contrast,
the ABCB1 level was signiﬁcantly decreased in ovarian carcinomas and
associated with FIGO stage and Ki-67 in our study. However, we did
not ﬁnd an association with the TTP of ovarian carcinoma patients. Re-
cently, a lack of ABCB1 deregulation in recurrent carcinoma lesions com-
pared with normal ovaries (n = 9) and benign ovarian cystadenomas
(n = 41) was observed in Austrian patients [19]. Moreover, a study on
Italian patients found no differences in ABCB1/P-gp expression levels
between sensitive and resistant patients (n = 41) [23], which seems
to further support our results. On the other hand, ABCB1 expression sig-
niﬁcantly elevated the risk of disease progression in ovarian carcinoma
patients before chemotherapy (n = 206) [17], even though it did not
correlate with the overall survival. Thus, a clinical relevance of ABCB1/
P-gp overexpression in ovarian carcinoma remains elusive. Interethnicdifferences in frequencies of ABCB1 polymorphisms arewell documented
[24] but their role in expression of the ABCB1 is unknown.Wemay spec-
ulate that discrepancies between the results of present and previous
studies could partly be due to this fact.
Apoptosis and mitotic exit are two possible fates following mi-
totic arrest [25]. Comparing resistant (NCI/ADR-RES) vs. sensitive
(MDA-MB-435) tumor cells, we have shown that pathways of apoptosis
induction by taxanes could differ in the activation of caspases [26].
Caspases are cysteine-dependent aspartate-directed proteases playing
an essential role in the execution phase of apoptosis. A key role of
caspase-2 in apoptosis induced by taxanes frequently used for ovarian
carcinoma treatment was previously suggested in vitro [27]. In our
study,we observed anoverexpression of CASP2 transcript in ovarian car-
cinoma vs. normal ovarian tissues and its association with high FIGO
stage. However, it should be emphasized that this analysis was under-
powered due to the low numbers of patients in the FIGO stage I/II
group and thus the results should not be overestimated. On the other
hand, CASP9 functionally associatedwith CASP2 expressionwas strongly
decreased in carcinoma vs. normal ovarian tissues and did not associate
with clinical factors or the TTP of ovarian carcinoma patients. Equally,
our study was unable to detect any association of CASP8 with ovarian
carcinoma. A previous study found that cleaved caspase-3 but not
caspase-8 level was associated with improved overall and progression-
free survival in ovarian carcinoma effusions from 52 patients [28].
An increased caspase-3 expression in post-chemotherapy ovarian or
tubal carcinomas compared with pre-chemotherapy specimens has
also been observed (n = 10) [29]. In another study, patients whose
post-chemotherapy biopsies expressed active caspase-3 in less than
50% of carcinoma cells had worse overall and progression-free survival
comparedwith patients expressing caspase-3 inmore than 50% of carci-
noma cells (n = 73) [30]. In our study, the transcript level of CASP3 did
not associate with the clinical factors or TTP of ovarian carcinoma pa-
tients, suggesting that the protein level and/or enzymatic activity of
caspase-3 rather than the transcript level may be responsible for the
previously observed association with prognosis of patients with ovarian
carcinomas. The gene expression proﬁle of CASP2 and CASP9, important
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been reported so far with regard to ovarian carcinoma.
Peritoneal tissueswere collected in order to compare expression dif-
ferences between tumor and non-neoplastic epithelial tissues from the
same patients. The presence of micrometastases in peritoneal samples
could not be histologically evaluated. Therefore, non-neoplastic sam-
ples from different patient group were used for additional comparison
to minimize a potential bias. Despite the fact that we have observed a
gradient in expression of all genes except caspaseswith peritoneal sam-
ples between tumor and non-neoplastic ovaries, our data should be
interpreted with caution.
In conclusion, our study has revealed signiﬁcant differences in
transcript levels of putative markers of resistance toward taxanes in
ovarian carcinomas compared with peritoneal or normal ovarian tis-
sues. ABCB1, CASP2, KIF14 and PRC1 associated with the established
clinical prognostic factors as FIGO stage and Ki-67 protein expression.
Furthermore, CIT associated with the TTP of ovarian carcinoma pa-
tients. The potential clinical utility of these markers needs to be eval-
uated by a larger independent follow up study.
4. Materials and methods
4.1. Patients
Tissue samples of human ovarian carcinomas were prospectively
obtained from 55 ovarian carcinoma patients diagnosed at the Faculty
Hospital Motol in Prague during the period 2009–2010. Carcinoma
samples were available from 55 patients and paired epithelial tissue
samples from peritoneum without morphological/macroscopic signs
of carcinoma presence were available for 51 patients. Samples of
ovarian tissue without histology-veriﬁed morphological/macroscopic
signs of carcinoma were obtained from 16 patients who underwent
gynecological surgery for diagnoses other than ovarian malignancy.
The tissues collected during surgery were histopathologically investi-
gated according to standard diagnostic procedures. Carcinoma speci-
mens were excised from the native tissue sample, transferred into
RNA later (Life Technologies Corp., Carlsbad, CA, USA) and stored at
4 °C until total RNA isolation. The remaining tissue that was collected
during surgery was histopathologically analyzed according to stan-
dard diagnostic procedures. The following data on patients were re-
trieved from medical records: the patient's age at diagnosis, FIGO
stage, the histological type and grade of the tumor, the type of surgi-
cal procedure, the chemotherapy regimens and the TTP in months.
Physical examinationswere performed and CA-125 levelswere obtained
after every chemotherapy cycle. Disease progression during follow up
was periodically monitored using physical, gynecological examinations
and CA-125 levels every 3 months, supplemented with computer to-
mography or ultrasound examination of the abdomen and pelvis every
six months for two years. All patients were asked to read and sign an
Informed Consent in accordance with the requirements of the Ethical
Commission of the National Institute of Public Health in Prague.
4.2. Isolation of total RNA and cDNA preparation
Total RNA was isolated using Trizol reagent as previously published
[31]. RNA was quantiﬁed using a Quant-iT RiboGreen RNA Assay Kit
(Invitrogen) and its quality was evaluated by measuring the RNA Integ-
rity Number (RIN) using Agilent 2100 Bioanalyzer (Agilent Technologies,
Inc., Santa Clara, California, USA). The RIN value was 6 on average (range
2–8). RNA was totally degraded in one carcinoma tissue sample and
therefore was not further evaluated. cDNA was synthesized using
0.5 μg of total RNA and its quality was conﬁrmed by PCR ampliﬁcation
of ubiquitin C fragment as described previously [31,32]. The prepared
cDNA was subsequently diluted in ratio 1:5 with Nuclease free water
(Life Technologies) and used for qPCR.4.3. Quantitative real-time PCR
qPCR was performed in RotorGene 6000 (Corbett Research, Sydney,
Australia). Reaction mixtures contained 5 μl of TaqMan® Gene Expres-
sion Master Mix (part no. 4370048, Life Technologies), 0.5 μl of speciﬁc
TaqMan Gene Expression Assays (Life Technologies, assays listed in
Table 1), 2.5 μl of diluted cDNA template and water to make a ﬁnal vol-
ume of 10 μl. Cycling parameters were initial hold at 50 °C for 2 min
and initial denaturation at 95 °C for 10 min, followed by 55 cycles
consisting of denaturation at 95 °C for 15 s and annealing/extension
at 60 °C for 60 s (except TBP where 60 °C for 90 s and ABCB1 and PPIA
where 58 °C for 60 s was used). Fluorescence was acquired after each
extension phase. Samples were analyzed in duplicates. Samples with
larger than 0.5 Ct variation between duplicates were reanalyzed. The
non-template control contained water instead of cDNA. Additionally,
negative cDNA synthesis controls (RNA transcribed without reverse
transcriptase) were employed to reveal possible carry-over contamina-
tion. In each run, an inter-plate calibrator was included to account for
any variations between runs. The relative standard curvewas generated
from 5 log dilutions of cDNA sample used as a calibrator. Ampliﬁcation
efﬁciencies for each reference and target gene were calculated applying
the formula E = 101/slope − 1. PPIA, TBP and GUSB (Table 1) were used
as the reference genes in accordancewith the previously reported study
on ovarian tissues [33]. The qPCR study design adhered to the MIQE
Guidelines (Minimum Information for Publication of Quantitative
Real-Time PCR Experiments, [34].
4.4. Immunohistochemical analysis of Ki-67 protein expression in
histological sections
Fresh tissue samples containing the ovarian carcinoma tissue were
ﬁxed in buffered 4% formaldehyde and embedded in parafﬁn. 3 μm
thin histological sections were cut and the ﬁrst slide was stained
with hematoxylin and eosin. The most appropriate region of carcino-
ma tissue was chosen for immunohistochemical evaluation of prolif-
eration activity. Primary antibody against Ki-67 antigen was used
(clone MIB-1, Dako, dilution 1:100). After deparafﬁnization and
rehydratation of tissue, the histological sections were pretreated by
heating in 10 mmol/l citrate buffer (pH 6.0) in water bath. Endoge-
nous peroxidase activity was blocked in 3% hydrogen peroxide.
Detection of primary antibody binding was performed using second-
ary biotinylated antibody, streptavidin-peroxidase complex and hy-
drogen peroxide/DAB (3,3′-diaminobenzidine tetra-hydrochloride).
The nuclear expression of Ki-67 was evaluated under a light micro-
scope. Besides the pattern of diffuse nuclear positivity of Ki-67, a relo-
cation of these proteins on the surface of chromosomes was found in
mitosis. The percentage of carcinoma cell positivity was scored
4.5. Data analysis
For statistical analyses of transcript levels, a ratio of Ct for a particular
target gene to an arithmetic mean of Ct for all reference (REF) genes
(target gene/REF) was calculated for each sample. Therefore, the lower
is the target gene/REF ratio the higher is the relative target gene tran-
script level. Mean Ct values were used for calculating of differences in
transcript levels between tissue types using REST 2009 Software (Qiagen,
Hildesheim, Germany), as published [35]. Associations of transcript
levels with clinical data – age at diagnosis in years; histological type
of ovarian carcinoma (serous vs. other); histological grade, G1 or G2 vs.
G3 or G4; FIGO stage, I or II vs. III or IV and Ki-67 expression in % – was
assessed by non-parametric Kruskal–Wallis and Spearman rank tests.
TTP was deﬁned as the time elapsed between the date of surgical treat-
ment and disease progression or cancer-related death. In the ﬁrst step,
patientswere divided into four groups using quartiles of the investigated
transcript levels. For these groups, the survival functionswere computed
by Kaplan–Meier method. Cut-offs deﬁned by quartiles were tested and
101M. Ehrlichova et al. / Genomics 102 (2013) 96–101the “optimal cut-off” was deﬁned as the highest statistical signiﬁcance
by log-rank test. All P-values were obtained from two-sided tests. A
P b 0.05 was considered statistically signiﬁcant. Statistical analyses
were performed using SPSS v16.0 software (SPSS Inc., Chicago, IL).
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